Reddy-Lenalidomide represents our firm commitment to providing access to affordable medicines for Canada’s Multiple Myeloma and Myelodysplastic Syndrome (MDS) patient population”. According to the data, both firms’ capsules come in doses of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg.
Glenn Ikeda, CEO of Natco Pharma (Canada) Inc, said, “We are proud to have led the way for an accessible treatment option for multiple myeloma that may alleviate the financial burden for myeloma patients, as well as public and private payers”. He also noted that the product launch is a significant step forward in Natco’s attempts to grow its product range, and it is also the outcome of significant Canadian investment that will save healthcare money at a vital time.
According to the data, the medicine is used in conjunction with dexamethasone to treat multiple myeloma patients who cannot undergo stem cell transplant. According to the researchers, it is also used to treat patients with transfusion-dependent anemia caused by low or intermediate-1-risk myelodysplastic syndromes linked with a deletion 5q cytogenetic abnormality with or without other cytogenetic abnormalities.
